Crowdacure is preparing to campaign for 5 research projects,
all being hard to fund or in underfunded areas of medical research. The projects are currently in peer-review hence they are not yet confirmed.
As soon as they are approved by the experts we will let you know in what fields is the research.
However, you will still need to be patient as we will work with them in taking the scientific material and make it easy to understand for all.
Last year, 2 research projects have campaigned with Crowdacure.
The first is a research project in multiple sclerosis ran by Prof Gavin Giovannoni, Prof Julian Gold and Dr David Holden (see below).
The second is a project in managing phantom limb pain with augmented reality lead by Professor Ali Mousavi (see below). The latter campaign has been interrupted to join the new campaign we are preparing.
You can see the completed multiple sclerosis campaigns below, and the phantom limb pain campaign, which is on hold.
Thank you to the donors!
Antony Michael grace
Brian James Malyon
Carlos Ollero Sánchez
christian van der ree
Javier Navarro Martínez
Jiri Doubekjo maclean
Jonathan Mark Massheder
Helle Kirstine Rosenmeier
Olivier Van Der Meeren
Richard William Stoner
Roisin Ni Thuama
Russell Johnson Kyle
vipra khanna malik
Multiple sclerosis might not just be an autoimmune disease. Viruses could participate in causing the disease. Help us find out if we can treat multiple sclerosis with antiviral drugs.
We will use Famciclovir
This generic drug has shown to reduce the activity of the Epstein-Barr virus. It has been administered to a small number of people with severe infectious mononucleosis. Compared to other available drugs we think it’s safer, cheaper and better tolerated.
It is very difficult to treat viruses.
Viruses are not alive, so they can’t be ‘killed’. We want to make sure the Famciclovir treatment reduces the activity of the virus. To do this we’ll compare how much of the virus is present before and after treatment.
What’s the best time of day to detect the virus?
We know we can detect the virus in saliva, but we don’t yet know how much virus is found in the saliva of people with MS, or when is the best time of day to detect it. The first step of our project is to find this out.
Measuring the presence of the EBV virus by
Take saliva samples to measure the virus
Make the virus DNA visible using polymerase chain reaction
Read and analyse the data
The Centre for Sport and Exercise Science at Sheffield Hallam University have recently conducted research on people with multiple sclerosis (Carter et al., 2014). As part of this research, they collected saliva samples from 120 people and have kindly shared them with us*.
We will measure how much viral DNA we find in the collected saliva samples from each patient at 8 am, 12 pm, 5 pm and 9 pm on the collection days. It’s possible that the presence of the virus DNA will vary throughout the day. The virus presence may not be stable over time.
*Ethical approval has already been obtained from the South Yorkshire Research Ethics Committee to analyse these samples.
Why are we measuring the EBV virus?
Every adult with multiple sclerosis has been infected with the Epstein-Barr virus at some point in their life and we want to discover its role in potentially causing the MS disease to develop.
The Epstein-Barr virus is well-known for causing the ‘kissing disease’ (infectious mononucleosis) and we know that if a person has had infectious mononucleosis as a teenager they are more likely to get multiple sclerosis as an adult.
We want to know what time of day to measure the presence of the virus, and how high the virus level is in patients before they start the treatment. We aim to have this information within three months. We will use our findings to design a pilot study on people with multiple sclerosis to see the effect of Famciclovir on the Epstein-Barr virus.
Why is this research hard to fund?
Private sector funding bodies generally do not give finance to projects that use a generic drug such as Famciclovir. In addition, viral hypothesis regarding multiple sclerosis is an alternative direction of research, with the main working hypothesis being autoimmunity. As this is a slightly unconventional approach it is harder to gather the necessary support and funding.
Thank you so much for partnering with us to make this project happen. Check back soon for updates on our progress. We hope to be able to share the results with you three months after the end of this campaign.
If you want to send your feedback to the research team you can leave a comment or email them at email@example.com.
A Proper Treatment for Phantom Limb Pain
Phantom Limb Pain affects 8 million amputees worldwide, with 2.5 million of these suffering a severe form of this agonising pain. Despite the number of sufferers, funding to advance medical research in phantom limb pain is insufficient, leaving them with no satisfying treatment.
What is Phantom Limb Pain
Phantom Limb Pain is an agonising and ongoing pain for as many as 8 million amputees worldwide – affecting patients who have lost a limb or part of the body to diabetes, cancer, infections, wars, accidents and electrocutions.
A nervous system disorder, symptoms of Phantom Limb Pain can include painful sensations of stabbing and electric shocks in the area where the limb was lost.
Even when limbs are replaced by prosthetics, many continue to suffer from the pain because the brain hasn’t accepted either the loss of the old and the replaced limb.
NOW Pioneering research led by Professor Ali Mousavi at Brunel University and Professor Jonathan Cole from Poole Hospital in the UK propose to advance virtual reality-based solutions that will deliver effective, personalised and accessible treatment for sufferers. Prof Ali Mousavi needs your support to help advance this research to change amputees’ lives forever. This is why he asked we help him to fundraise. Together you are putting research for a better treatment for phantom limb pain on the agenda.
It is on hold to join the pooled campaign end of 2017
For any information please do not hesitate to contact
Dr Sagit Weiss at firstname.lastname@example.org